CSIMarket
 
Beigene ltd   (BGNE)
Other Ticker:  
 
 
Price: $170.0000 $1.10 0.651%
Day's High: $171.79 Week Perf: 3.32 %
Day's Low: $ 166.90 30 Day Perf: 16.54 %
Volume (M): 350 52 Wk High: $ 272.49
Volume (M$): $ 59,534 52 Wk Avg: $194.89
Open: $171.79 52 Wk Low: $132.95



 Market Capitalization (Millions $) 230,601
 Shares Outstanding (Millions) 1,356
 Employees 4,344
 Revenues (TTM) (Millions $) 2,458
 Net Income (TTM) (Millions $) -882
 Cash Flow (TTM) (Millions $) -689
 Capital Exp. (TTM) (Millions $) 581

Beigene Ltd
BeiGene Ltd is a globally recognized, commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative and targeted oncology therapeutics for patients across the globe. It was founded in 2010 in China by Dr. John Oyler and continues to operate with a primary focus on developing and commercializing innovative immuno-oncology medicines for patients with cancer.

Over the years, the company has expanded and become an integrated global biopharmaceutical company. It currently boasts of a comprehensive portfolio of oncology assets that includes both commercial-stage products and clinical candidates. The company aims to provide cancer therapies that are supported by extensive clinical research and innovative medicines that are tailored to meet the unique genetic and molecular characteristics of tumors.

Beigene Ltd's most successful product to date is the anti-PD-1 antibody Tislelizumab, which is approved by China's National Medical Products Administration (NMPA) for the treatment of various types of cancer. It is also in advanced clinical development for multiple cancer indications in the US and other regions across the world.

In addition to Tislelizumab, the company has an extensive pipeline on multiple late-stage clinical programs, including the Bruton tyrosine kinase (BTK) inhibitor, Zanubrutinib, an investigational RXDX-106, a small molecule selective inhibitor of mutant RET for the treatment of solid tumors, and several other candidate therapies in advanced stages of clinical development.

The company's innovative and globally recognized research and development program have positioned it to become a leader in developing clinically differentiated and unique oncology drugs. Its therapeutic approach employs targeted and precision medicine-based solutions to combat and eradicate cancer cells.

As a result of its remarkable efforts, BeiGene Ltd has entered into numerous strategic collaborations with major global pharmaceutical companies to develop innovative therapies for patients with cancer. These collaborations have not only expanded the company's global reach but also broadened its expertise and capabilities in the development of innovative oncology drugs.

Beigene Ltd is committed to applying its vast scientific expertise and resources towards making significant progress in oncology treatment for patients globally. The company boasts a truly global presence with headquarters in Beijing, China and its research center in Massachusetts, USA; and offices in Europe and other regions across the globe. With its core focus on developing and offering innovative cancer therapies that cater to the specific health needs of patients across the globe, BeiGene Ltd continues to remain a leader in the global biopharmaceutical industry.


   Company Address: c/o Mourant Governance Services (Cayman) Limited Grand Cayman 0
   Company Phone Number: 949 4123   Stock Exchange / Ticker: NASDAQ BGNE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

BeiGene's Tislelizumab Receives Encouraging FDA Approval for Esophageal Squamous Cell Carcinoma

Published Sat, Mar 16 2024 3:18 PM UTC

In recent news, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) announced its successful FDA approval for the use of tislelizumab-jsgr, commercially known as TEVIMBRA, as a treatment option for patients diagnosed with advanced or metastatic esophageal squamous cell carcinoma (ESCC). This landmark approval marks a significant milestone in the field of biopharmaceutica...

Product Service News

FDA Approves TEVIMBRA for Treatment of Inoperable or Metastatic Esophageal Squamous Cell Carcinoma

Published Fri, Mar 15 2024 6:06 AM UTC

Title for the article: BeiGene Receives FDA Approval for TEVIMBRA in the Treatment of Advanced or Metastatic Esophageal Squamous Cell CarcinomaBeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA (tislelizumab-jsgr) as a monotherapy for the treatme...

Product Service News

BeiGene's Breakthrough: FDA Approval Paves the Way for TEVIMBRA in Treating Advanced Esophageal Squamous Cell Carcinoma

Published Thu, Mar 14 2024 8:28 PM UTC

BeiGene, a renowned global oncology company, recently received FDA approval for its breakthrough drug, TEVIMBRA (tislelizumab-jsgr), as a monotherapy for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC). This approval marks a significant milestone for the company and offers new hope for patients who have previously undergone ...

Business Update

BeiGene's BRUKINSA Receives FDA Approval with Superior Progression-Free Survival Results, Fueling Company's Global Growth and Success

Published Wed, Feb 28 2024 11:48 AM UTC

BeiGene, a global biotechnology company, has recently received FDA approval for a label update on BRUKINSA (zanubrutinib). The update includes superior progression-free survival (PFS) results from the Phase 3 ALPINE trial, which compared BRUKINSA against IMBRUVICA (ibrutinib) in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This...

Business Update

BeiGene Reports Strong Global Growth in 2023 with Impressive Financial Results

Published Tue, Feb 27 2024 3:22 AM UTC

BeiGene, a global biotechnology company specializing in the field of oncology, has announced its continued expansion on a global scale, significant revenue growth worldwide and in the United States, and an innovative research and development strategy. This article aims to provide an overview of BeiGene's financial performance for the fourth quarter of 2023, as well as key u...






 

Beigene Ltd's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Beigene Ltd does not provide revenue guidance.

Earnings Outlook
Beigene ltd does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com